Johnson & Johnson Pte Ltd
|Title of Study||
A multicenter, prospective, longitudinal registry of patients with prostate cancer in Asia
This observational registry aims to document PC disease in routine clinical practice in Asia, regardless of treatment used. The objectives of this registry are:
1.To document PC management including diagnosis, prognosis, treatment, and care in real-world practice.
2.To observe the clinical progression and outcomes of PC, such as overall survival (OS), PC-related mortality (PM), metastasis-free survival (MFS), progression-free survival (PFS), and time to PSA progression (TTPP).
3.To examine considerations of, duration of, and adherence to PC treatments.
4.To assess PROs on HRQoL.
5.To examine the association of multiple risk factors with disease progression.
|Number of Sites||
Taiwan:2 ; Global:38
|Period of Study||
From：September 9, 2015 to：September 15, 2020
|Number of Patients||
|IRB Approval Date||
NTUH: October 6, 2015
KSVGH: September 10, 2015
|Publication Plan / Date||
January 3, 2021